Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 429

The DOI matches its Crossref record.

Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial

Open access
Ellis, Charles N., Fradin, Mark S., Messana, Joseph M., Brown, Marc D., Siegel, Michael T., Hartley, A. Howland, Rocher, Leslie L., Wheeler, Suzanne, Hamilton, Ted A., Parish, Thomas G., Ellis-Madu, Mary, Duell, Elizabeth, Annesley, Thomas M., Cooper, Kevin D., Voorhees, John J.·1991·New England Journal of Medicine

Abstract

BACKGROUND: Severe plaque-type psoriasis has been successfully treated with orally administered cyclosporine, but there has been no comparative, controlled evaluation of various dosages and their efficacy and side effects. METHODS: In a 16-week, double-blind trial, we randomly assigned 85 patients with severe psoriasis to receive 3, 5, or 7.5 mg of cyclosporine per kilogram of body weight per day or a placebo consisting of the vehicle for the drug. After eight weeks the dose could be adjusted to improve safety or efficacy while maintaining blinding. RESULTS: The psoriasis improved in a dose-dependent fashion. After eight weeks of fixed-dose therapy, 36, 65, and 80 percent of the patients receiving 3, 5, and 7.5 mg of cyclosporine per kilogram per day, respectively, were rated as being clear or almost clear of psoriasis; each group had significant improvement (P less than 0.0001) as compared with the group receiving vehicle, in which none of the patients were rated as clear or almost clear. The patients who received 5 mg per kilogram were the least likely to require dosage adjustments because of side effects or a lack of efficacy. The glomerular filtration rate, measured in a subgroup of 34 patients receiving cyclosporine, decreased by a median of 16 percent. Higher doses of cyclosporine had greater adverse effects on systolic blood pressure, glomerular filtration rate, and serum levels of creatinine, uric acid, bilirubin, and cholesterol. Delayed-type hypersensitivity reactions to skin-test antigens were reduced by cyclosporine administration. Cyclosporine appears to become concentrated in skin. CONCLUSIONS: Cyclosporine therapy leads to a rapid and thorough clearing of psoriasis; an initial dose of 5 mg per kilogram per day seems to be appropriate. However, the safety of cyclosporine for the long-term treatment of psoriasis remains to be determined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199101313240501

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 429

Metadata

Authors
Ellis, C. N., Fradin, M. S., Messana, J. M., Brown, M. D., Siegel, M. T., Hartley, A. H., Rocher, L. L., Wheeler, S., Hamilton, T. A., Parish, T. G., Ellis-Madu, M., Duell, E., Annesley, T. M., Cooper, K. D., & Voorhees, J. J.
Venue
New England Journal of Medicine
Published
1991-01-31
Volume
324
Issue
5
Pages
277-284
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2019276276
Cited by
429
References
0
FWCI
13.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial. https://app.cochat.ai/papers/10.1056/nejm199101313240501
The paper
Ellis, C. N., Fradin, M. S., Messana, J. M., Brown, M. D., Siegel, M. T., Hartley, A. H., Rocher, L. L., Wheeler, S., Hamilton, T. A., Parish, T. G., Ellis-Madu, M., Duell, E., Annesley, T. M., Cooper, K. D., & Voorhees, J. J. (1991). Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial. New England Journal of Medicine. https://doi.org/10.1056/nejm199101313240501

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.